You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

MINIZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Minizide patents expire, and what generic alternatives are available?

Minizide is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in MINIZIDE is polythiazide; prazosin hydrochloride. There is one drug master file entry for this compound. Additional details are available on the polythiazide; prazosin hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MINIZIDE?
  • What are the global sales for MINIZIDE?
  • What is Average Wholesale Price for MINIZIDE?
Summary for MINIZIDE
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 7
Patent Applications: 7
DailyMed Link:MINIZIDE at DailyMed
Drug patent expirations by year for MINIZIDE

US Patents and Regulatory Information for MINIZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MINIZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MINIZIDE

See the table below for patents covering MINIZIDE around the world.

Country Patent Number Title Estimated Expiration
Philippines 13965 METHODS FOR TREATING CONGESTIVE HEART FAILURE AND ISCHEMIC HEART DISEASE ⤷  Sign Up
Belgium 868843 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.